Patents by Inventor Baltazar Gomez-Mancilla

Baltazar Gomez-Mancilla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
    Publication number: 20150275303
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Application
    Filed: June 10, 2015
    Publication date: October 1, 2015
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • ORGANIC COMPOUNDS
    Publication number: 20150272929
    Abstract: The invention concerns the use an mGluR modulator, e.g.
    Type: Application
    Filed: June 11, 2015
    Publication date: October 1, 2015
    Inventors: Daniel UMBRICHT, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Therese Di Paolo
  • COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
    Publication number: 20140228398
    Abstract: The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: March 16, 2012
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: Therese Di Paolo, Baltazar Gomez-Mancilla, Cristina Lopez-Lopez, Donal Johns
  • COMBINATION PRODUCTS
    Publication number: 20140194423
    Abstract: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.
    Type: Application
    Filed: March 4, 2014
    Publication date: July 10, 2014
    Inventors: Baltazar Gomez-Mancilla, Fabrizio Gasparini
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20140171448
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of a Movement Disorder selected from Dystonia, Dyskinesia, Chorea, Restless Legs Syndrome, Tics, Tremor, Myoclonus, Startle, Stiff Person Syndrome, Gait Disorder, Parkinson's Disease and Symptomatic Parkinsonism.
    Type: Application
    Filed: January 20, 2012
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Cristina Lopez-Lopez, Donald Johns, Thérése Di Paolo
  • Combination products
    Patent number: 8703809
    Abstract: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: April 22, 2014
    Assignee: Novartis AG
    Inventors: Baltazar Gomez-Mancilla, Fabrizio Gasparini
  • Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS)
    Publication number: 20130052644
    Abstract: The invention is directed to the use of biomarkers to determine responsiveness of an individual with Fragile X Syndrome (FXS) to treatment with an mGluR5 antagonist.
    Type: Application
    Filed: April 28, 2011
    Publication date: February 28, 2013
    Inventors: Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Joanne Meyer, Charles Paulding
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20120172346
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Application
    Filed: September 22, 2010
    Publication date: July 5, 2012
    Inventors: Thérèse Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA
    Publication number: 20120157464
    Abstract: The invention concerns the use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment, prevention or delay of progression of ataxia.
    Type: Application
    Filed: July 21, 2010
    Publication date: June 21, 2012
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla
  • COMBINATION PRODUCTS
    Publication number: 20120122878
    Abstract: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.
    Type: Application
    Filed: June 30, 2008
    Publication date: May 17, 2012
    Inventors: Baltazar Gomez-Mancilla, Fabrizio Gasparini
  • COMBINATIONS FOR THE TREATMENT OF MIGRAINE
    Publication number: 20110212980
    Abstract: The present invention relates to novel combinations suitable for the treatment of migraine of various genesis or aetiology, which comprise, as active ingredients, at least one 5-HT1 B/1 D receptor agonist and at least one selective, competitive AMPA receptor antagonist being a 1 H-quinazoline-2,4-dione of formula (I) as defined in the claims; to their preparation; to their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: October 21, 2009
    Publication date: September 1, 2011
    Inventors: Graeme Bilbe, Baltazar Gomez-Mancilla, Daniel Hoyer, Donald Johns, Hans O. Kalkman, Kevin Hall Mcallister
  • ORGANIC COMPOUNDS
    Publication number: 20100249136
    Abstract: The invention concerns the use an mGluR modulator, e.g.
    Type: Application
    Filed: October 9, 2008
    Publication date: September 30, 2010
    Inventors: Daniel Umbricht, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Therese Di Paolo
  • BioMarkers for the Progression of Alzheimer's Disease
    Publication number: 20100035251
    Abstract: The genetic polymorphism LRRK2 (leucine-rich repeat kinase 2)-T1602S is significantly associated with conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), with the patients with TT genotype being at greater risk to progress to Alzheimer's disease. The LRRK2-T2352 also showed a trend for conversion to Alzheimer's disease, with the patients with CC genotype tending to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, LRRK2-T1602S and LRRK2-T2352 showed a greater association with the rate of conversion from mild cognitive impairment to Alzheimer's disease. In another study with placebo-treated Alzheimer's disease patients, LRRK2-T1602S and LRRK2-T2352 showed a same trend of association. The Alzheimer's disease patients with TT genotype of LRRK2-T1602S or CC genotype of LRRK2-T2352 tended to decline faster on cognitive performance over 6 months, especially in the presence of a BuChE-K variant.
    Type: Application
    Filed: June 18, 2007
    Publication date: February 11, 2010
    Inventors: Yunsheng He, Baltazar Gomez-Mancilla, Joanne Meyer, Giorgio Rovelli, Graeme Bilbe
  • Cabergoline and pramipexole: new uses and combinations
    Publication number: 20030045539
    Abstract: This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.
    Type: Application
    Filed: October 16, 2002
    Publication date: March 6, 2003
    Inventor: Baltazar Gomez-Mancilla
  • Cabergoline and pramipexole: new uses and combinations
    Patent number: 6503920
    Abstract: This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: January 7, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Baltazar Gomez-Mancilla
  • Use of pramipexole in the treatment of restless legs syndrome
    Patent number: 6194445
    Abstract: The present invention provides the use of pramipexole in the treatment of restless legs syndrome.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: February 27, 2001
    Assignees: Pharmacia & Upjohn Company, Boehringer Ingelheim Pharma KG
    Inventors: Wolfgang H. Oertel, Dieter Meier, Baltazar Gomez-Mancilla, Jacques Montplaisir
  • Use of pramipexole in the treatment of restless legs syndrome
    Patent number: 6001861
    Abstract: The present invention provides the use of pramipexole in the treatment of restless legs syndrome.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: December 14, 1999
    Assignee: Pharmacia & Upjohn Company
    Inventors: Wolfgang H. Oertel, Dieter Meier, Baltazar Gomez-Mancilla, Jacques Montplaisir